Orthocell has submitted a regulatory application to the British Standards Institution (BSI) seeking approval to commercially distribute Remplirâ„¢ in the European Union and United Kingdom, a combined nerve repair market valued at approximately US$750 million and comprising an estimated 500,000 peripheral nerve repair procedures each year.
Orthocell Strengthens Asian Growth Platform with First Commercial Sales in Hong Kong
Orthocell has announced that it has completed the first commercial sales of Remplir™ in Hong Kong, representing a key milestone in the Company’s Asian growth strategy.
Remplirâ„¢ Nerve Sparing Prostate Cancer Surgery Commercial Opportunity Gathers Momentum
Momentum is growing for Remplir™ in nerve-sparing prostate cancer surgery, with around 100 surgeries now performed using the flagship nerve repair device.Â
Orthocell Appoints Second Canadian Distributor for Remplirâ„¢
Orthocell has appointed its second distributor in Canada. The appointment completes national coverage across the US$75 million Canadian market, ensuring access for patients and healthcare providers nationwide.
First Remplirâ„¢ Surgical Case Completed in Hong Kong
Orthocell has announced the successful completion of the first Remplirâ„¢ surgical case in Hong Kong and the official launch of their flagship nerve repair medical device at the Hong Kong Orthopaedic Association (HKOA) 45th Annual Congress.
Professor Minghao Zheng elected Fellow of the Australian Academy of Health and Medical Sciences Â
Professor Minghao Zheng, Orthocell’s Co-Founder and Chief Scientific Officer, has been elected as a Fellow of the Australian Academy of Health and Medical Sciences (AAHMS).
Orthocell Appoints Exclusive Remplirâ„¢ Distributor for Hong Kong
Orthocell has appointed medical device distributor MontsMed as its exclusive in-country distributor for Remplir in the key Asian market of Hong Kong.
Orthocell secures global distribution rights to innovative bone regeneration technology
Orthocell has signed Memorandum of Understanding to increase its equity stake in Marine Biomedical – from 1.7% to 12.0% for a total consideration of AU$1.0 million – securing exclusive first right of refusal over global distribution rights their groundbreaking bone substitute product, PearlBoneâ„¢.
$30.0 Million Placement to Accelerate Global Commercialisation and Advance Product Portfolio
Orthocell has today announced that it has received firm commitments for a $30 million capital raising via an institutional placement.
Quarterly Report – period ended 30 September 2025
Orthocell has today released its Quarterly Report for the period ended 30 September 2025, outlining a period of continued growth and strong commercial progress.